1. Antilymphoma therapy with a Bcl-6 inhibitor

   • Peter McLaughlin

   Clinical Trials Report 01 October 2009 Pages: 183 - 184

2. Chemoimmunotherapy with modified dosing of fludarabine, cyclophosphamide, and rituximab shows significant clinical activity in patients with previously untreated chronic lymphocytic leukemia

   • Nicole Lamanna
   • Mark A. Weiss

   Clinical Trials Report 01 October 2009 Pages: 185 - 186

3. Vaccination strategies in follicular lymphoma

   • Shibichakravarthy Kannan
   • Sattva S. Neelapu

   OriginalPaper 01 October 2009 Pages: 189 - 195

4. The host-tumor interface in B-cell non-Hodgkin lymphoma: A new world to investigate

   • Nicolas Rachinel
   • Gilles Salles

   OriginalPaper 01 October 2009 Pages: 196 - 201

5. Prognostic factors in low-grade non-Hodgkin lymphomas

   • Massimo Federico
   • Stefano Molica
   • Stefano Luminari

   OriginalPaper 01 October 2009 Pages: 202 - 210

6. Frontline therapy in mantle cell lymphoma: The role of high-dose therapy and integration of new agents

   • Brad S. Kahl

   OriginalPaper 01 October 2009 Pages: 213 - 217

7. Beyond R-CHOP and the IPI in large-cell lymphoma: Molecular markers as an opportunity for stratification

   • Jason R. Westin
   • Luis E. Fayad

   OriginalPaper 01 October 2009 Pages: 218 - 224

8. Update on the World Health Organization classification of peripheral T-cell lymphomas

   • Hilary M. O’Leary
   • Kerry J. Savage

   OriginalPaper 01 October 2009 Pages: 227 - 235

9. Hemopoietic stem cell transplantation in T-cell malignancies: Who, when, and how?

   • Francesco d’Amore
   • Esa Jantunen
   • Thomas Relander

   OriginalPaper 01 October 2009 Pages: 236 - 244

10. Natural killer-cell neoplasms

    • John P. Greer
    • Claudio A. Mosse

    OriginalPaper 01 October 2009 Pages: 245 - 252